Versuchen GOLD - Frei

Business

BioSpectrum Asia

BioSpectrum Asia

Thailand's Life Sciences Push Gains Business Momentum

Thailand, emerging as a life sciences hub, fueled by biotech startups, multinational investment, and government-backed research in vaccines, genomics, and regenerative medicine, is positioning itself as ASEAN’s leading center for healthcare innovation.

2 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

'Point of care will change the CDMO business structure from Centralised to De-Centralised cell manufacturing”

With Japan emerging as a hub for regenerative medicine innovation, Teijin Regenet—a Teijin Group company— has become a key player driving next-generation manufacturing and CDMO growth.

2 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

RedHill Biopharma signs $1.8 M deal to accelerate Talicia's entry into new Middle East markets

Red Hill Biopharma, a US-based specialty biopharmaceutical company, has announced the licensing of Talicia for new Middle East markets in a deal worth potentially $1.8 million plus sales royalty payments.

1 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

Mirxes' non-invasive microRNA blood test secures approval in China for gastric cancer screening

Singapore-based Mirxes has been granted regulatory approval for its flagship product, GASTROClear, by China's National Medical Products Administration (NMPA).

1 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

EXPEDITING APPROVALS OF SAFE & AFFORDABLE BIOSIMILARS

While the world is discussing and troubled over 100 per cent tariffs on medicines announced just over a month back by the US administration, there is a music played to the ear of pharma producers in Asia. This music was played by the US Food and Drug Administration (FDA) last week when it made a major announcement over approvals of biosimilars, generic versions of complex biological drugs, that treat serious and chronic diseases.

2 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

Policy Reforms Give India's MedTech Sector a Global Edge

Since medical technology (MedTech) is a sunrise industry, the government is giving it priority to support patient-centric growth, while also concentrating on lowering reliance on imports and aligning regulations with international norms. With a focus on capital, incubation, talent development, and market access, the Indian government has started a broad range of programmes to support MedTech firms. This article examines governmental and regulatory efforts, emphasizing how policy-driven assistance is helping MedTech businesses become more globally competitive.

6 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

The Zika Comeback: One Vaccine, One Hope

Asia, the epicenter of flaviviruses like Japanese encephalitis (JE), dengue, and Zika, faces both a critical need and a strategic opportunity to lead vaccine development. Phylogenetic evidence shows that the Zika strain behind the Americas outbreak originated in Southeast Asia. With global pipelines favouring high-income markets, regional biotech can drive preventive solutions, scale production, and avert outbreaks as Zika quietly resurfaces across Southeast Asia.

4 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

SK Biopharma announces Joint Venture with Eurofarma for AI-based epilepsy management

SK Biopharmaceuticals, a South Korean biotech company focusing on research, development, and commercialisation of treatments for disorders of the central nervous system (CNS) and oncology worldwide, has announced the establishment of Mentis Care, Inc., a joint venture with a leading Brazil-based pharmaceutical company, Eurofarma, with presence in 24 countries, including North America, Latin America and Africa, to commercialise an AI-based epilepsy management platform.

1 min  |

BioSpectrum Asia Nov 2025
BioSpectrum Asia

BioSpectrum Asia

India signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

New Zealand to lead new gene therapy trial for muscular dystrophy

The first clinical trial of a new treatment for a rare form of muscular dystrophy is being led by New Zealand-based University of Auckland's Centre for Brain Research.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Scientists in Australia grow living skin in world-first

Australia's University of Queensland (UQ) researchers have been the first in the world to successfully grow fully functioning human skin in a laboratory.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

India joins Health AI Global Regulatory Network to strengthen oversight of AI in healthcare

HealthAI - The Global Agency for Responsible AI in Health, has welcomed India as a pioneer country joining the HealthAI Global Regulatory Network (GRN), a global network of health regulators dedicated to the safe and effective use of artificial intelligence (AI) in healthcare.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

TVM Capital Healthcare announces first closing of $150 M Southeast Asia Fund

Singapore-based TVM Capital Healthcare, a global private equity investor and operator specialised in healthcare growth capital across emerging markets, has announced the first closing of its $150 million TVM Healthcare Southeast Asia Fund (SEA Fund).

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

National Yang Ming Chiao Tung University, TSH Biopharm collaborate to foster pharma talent in Taiwan

Taiwan's National Yang Ming Chiao Tung University (NYCU) and TSH Biopharm have signed a five-year industry-academia collaboration Memorandum of Understanding (MOU).

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Fujifilm Biosciences introduces BalanCD HEK293 Perfusion A Medium

Fujifilm Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, has announced the commercial launch of BalanCD HEK293 Perfusion A.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Korea makes smart patch that can run tests using sweat instead of blood

A research team at Korea Advanced Institute of Science and Technology has developed a smart patch that can precisely observe internal changes through sweat when simply attached to the body.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

ADB approves $106.9 M to strengthen secondary healthcare services in Sri Lanka

The Asian Development Bank (ADB) has approved a $106.9 million financing package to strengthen Sri Lanka's secondary curative care services, improve communicable disease prevention and control, and enhance the healthcare sector's governance and management capacity.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Epigenic Therapeutics raises $60 M to accelerate clinical development of medicines

China-based startup Epigenic Therapeutics, a clinical-stage innovative drug development company, has announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Partners and OrbiMed, and addition of new investors including IFSC and a renowned investment firm in the industry.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Avasa secures funding to proceed with US FDA clearance

Auckland-based medtech startup Avasa has secured the first close of its Pre-Series-A capital raise.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

WHO publishes report to help countries ensure equitable access to controlled medicines

The World Health Organization (WHO) has published the full edition of its guideline on balanced national controlled medicines policies, marking the first comprehensive global framework designed to ensure access to controlled drugs for medical and scientific uses, while minimising risks to public health that may arise due to misuse and diversion.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Nanyang Biologics partners with NVIDIA, HPE & Equinix to build AI-powered drug discovery platform

Nanyang Biologics (NYB) enters a strategic collaboration with NVIDIA, Hewlett Packard Enterprise (HPE), and Equinix to build 'VECURA'-an artificial intelligence (AI)-powered drug discovery platform that combines advanced predictive models with a proprietary library of millions of natural compounds.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

New Mpox vaccine study to launch in outbreak-affected DRC

New research due to launch in the Democratic Republic of the Congo (DRC) will provide important real-world data on the performance of the LC16m8 mpox vaccine in African populations, amid a major outbreak of the deadly virus which remains a continental public health emergency.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

Australia to implement new pneumococcal vaccine on National Immunisation Programme

Australian children will now have stronger protection against pneumococcal with the Australian Government implementing a new and improved vaccine on the National Immunisation Programme (NIP).

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

CUREator backs Monash biotech to advance new therapeutics for polycystic kidney disease

xCystence Bio, a Monash University biotech startup, has secured a top-up funding boost from Brandon BioCatalyst's CUREator incubator to drive the development of urgently needed therapeutics for Polycystic Kidney Disease (PKD).

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

HKMU licenses tech for non-invasive prostate cancer screening

Hong Kong Metropolitan University (HKMU) recently achieved its first-ever technology licensing agreement, a milestone in the University's efforts to translate research into impactful, real-world applications.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

PAHO intensifies call to strengthen vaccination in light of rising measles cases

The Pan American Health Organization (PAHO) is urging countries in the Americas to strengthen vaccination efforts, improve surveillance, and accelerate outbreak response following a rise in measles cases in the region.

1 min  |

BioSpectrum Asia Oct 2025

BioSpectrum Asia

Trump's Counter Productive Tariff Moves

On September 25, 2025, US President Donald Trump announced that the United States would impose a 100 per cent tariff on all branded and patented pharmaceutical imports starting October 1, unless the companies importing them are actively building manufacturing facilities in the US, defined as “breaking ground” or “under construction.” As of September 26, no official guidance or regulations had been released regarding how this policy would be implemented. The announcement has raised significant concerns from healthcare stakeholders, particularly the American Hospital Association (AHA), which represents nearly 5,000 hospitals, health systems, networks, and 43,000 individual members.

2 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

US FDA grants accelerated approval to first treatment for Barth Syndrome

The US Food and Drug Administration (FDA) has granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome, in patients weighing at least 30 kg.

1 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

"Sebia India will introduce pipeline of new products across Autoimmunity, Infectious Diseases"

France headquartered Sebia, a global leader in specialty diagnostics, is continuing its geographic footprint to better serve its customers. Over the decades, the company has earned worldwide recognition for its pioneering expertise in Multiple Myeloma screening, diagnosis, and monitoring, as well as its leadership in hemoglobinopathies diagnosis. In recent years, Sebia has significantly expanded its portfolio in autoimmunity and infectious disease diagnostics through strategic acquisitions – ORGENTEC in 2021 and ZEUS Scientific in 2022. The company is now all set to strengthen its presence in India, thereby expanding its reach, building talent, and raising awareness. Sebia established its presence in India in 2019, and has achieved consistent double-digit growth year after year. To find out more about the company's growth plans in India, BioSpectrum spoke to Heejin Roh, Vice President – Commercial Operations, Asia Pacific, Sebia. Edited excerpts:

4 min  |

BioSpectrum Asia Oct 2025
BioSpectrum Asia

BioSpectrum Asia

UK offers free chickenpox vaccination for first time to children

Thousands of children will be protected against chickenpox for the first time in England through a new vaccination programme that will keep kids in school and parents in work while also saving the National Health Service (NHS) vital funds.

1 min  |

BioSpectrum Asia Oct 2025